Breast Cancer | Specialty

Genomic Testing in Breast Cancer

February 2nd 2016

Treating Intermediate Risk Individuals with Breast Cancer

February 2nd 2016

Borgen Blasts USPSTF Breast Cancer Screening Guidelines

February 1st 2016

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.

Breast Cancer Chemoprevention: Targeting the Estrogen Receptor

January 31st 2016

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

Olaparib Studies Put Focus on BRCA-Positive Breast Cancers

January 30th 2016

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

Dr. Aditya Bardia on RAD1901 in ER-Positive Metastatic Breast Cancer

January 29th 2016

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.

HER2 Subtype Offers Clues for Individualizing Breast Cancer Care

January 29th 2016

One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy.

Dr. Peter Beitsch on Pertuzumab in Luminal Subtype Breast Cancer

January 18th 2016

Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.

Study Reveals New Potential Breast Cancer Drug Combinations

January 18th 2016

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

Dr. Danciu on Prescreening and Identifying Breast Cancer Survivors

January 18th 2016

Oana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.

A Second Chance

January 17th 2016

Tailoring your approach to how you interact with a patient can be beneficial.

Expert Explains USPSTF Breast Cancer Screening Guidelines

January 15th 2016

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.

Dr. Iwase on Elevated Neutrophil to Lymphocyte Ratio to Predict Survival Outcome in TNBC

January 14th 2016

Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.

Hope Rugo on Pembrolizumab's Potential in ER+/HER2- Breast Cancer

January 12th 2016

Hope Rugo, MD, discusses the phase Ib KEYNOTE-028 trial and the impact of its results thus far, as well as the design, findings, and next steps for the trial.

Final USPSTF Guidelines Scale Back Breast Cancer Screening

January 11th 2016

The US Preventive Services Task Force has issued final guidelines that stand by its recommendation that women at average risk of breast cancer should not start routine screenings until they reach age 50 years and that they should then undergo testing every 2 years.

Dr. Mamounas on Future of Surgical Treatments in Breast Cancer

January 5th 2016

Eleftherios P. Mamounas, MD, surgical oncologist, UF Health Cancer Center - Orlando Health, shares the future of surgical treatments for patients with breast cancer.

FDA Approves Alcohol-Free Docetaxel Formulation

December 28th 2015

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

Prophylactic Loperamide Reduces Neratinib-Related Diarrhea in HER2+ Breast Cancer

December 22nd 2015

Grade 3 diarrhea occurred in 16% of patients treated with neratinib and prophylactic loperamide, representing a significant reduction compared with phase III findings from the ExteNET trial.

Effective Management and Prevention of Neratinib-Induced Diarrhea

December 18th 2015

Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.

Trial Backs 50-Gene Test in Neoadjuvant Setting

December 18th 2015

Neoadjuvant chemotherapy for women diagnosed with breast cancer can help shrink a tumor prior to surgery, which can make the procedure minimally invasive and potentially influence prognosis.